ICER Pushes ALS Drug Makers To Moderate Launch Price While Awaiting Confirmatory Data
Executive Summary
The US drug pricing watch dog issued a final assessment on Amylyx's AMX0035 and Mitsubishi Tanabe's Radicava for ALS.
Topics
- Subjects
- Pricing Debate
- Advisory Committees
- Market Access
- Pricing Strategies
- Commercial
- Business Strategies
- Therapy Areas
- Neurology
Latest Headlines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
SC147049
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.
All fields are required.
SC147049
Email Article
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.